These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 17550957)

  • 1. Association between a C/T polymorphism in exon 33 of the thyroglobulin gene is associated with relapse of Graves' hyperthyroidism after antithyroid withdrawal in Taiwanese.
    Hsiao JY; Hsieh MC; Tien KJ; Hsu SC; Shin SJ; Lin SR
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3197-201. PubMed ID: 17550957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exon 33 T/T genotype of the thyroglobulin gene is a susceptibility gene for Graves' disease in Taiwanese and exon 12 C/C genotype protects against it.
    Hsiao JY; Hsieh MC; Tien KJ; Hsu SC; Lin SR; Ke DS
    Clin Exp Med; 2008 Mar; 8(1):17-21. PubMed ID: 18385936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic T lymphocyte-associated molecule-4 polymorphism and relapse of Graves' hyperthyroidism after antithyroid withdrawal.
    Wang PW; Liu RT; Juo SH; Wang ST; Hu YH; Hsieh CJ; Chen MH; Chen IY; Wu CL
    J Clin Endocrinol Metab; 2004 Jan; 89(1):169-73. PubMed ID: 14715845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of endothelin 1 (G5665T and T-1370G) and endothelin receptor type A (C+70G and G-231A) in Graves' disease.
    Aydın AF; Develi-İş S; Doğru-Abbasoğlu S; Vural P; Ozderya A; Karadağ B; Uysal M
    Int Immunopharmacol; 2014 Jan; 18(1):198-202. PubMed ID: 24291390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of CTLA-4 and Tg polymorphisms in the recurrence of Graves' disease after antithyroid withdrawal.
    Tanrikulu S; Erbil Y; Ademoglu E; Işsever H; Barbaros U; Kutlutürk F; Ozarmagan S; Tezelman S
    Endocrine; 2006 Dec; 30(3):377-81. PubMed ID: 17526951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease.
    Kim KW; Park YJ; Kim TY; Park DJ; Park KS; Cho BY
    Thyroid; 2007 Dec; 17(12):1229-34. PubMed ID: 17949264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No association between Fas A/G polymorphism and therapeutic effects induced by methimazole treatment for Graves' disease in Northern Chinese.
    Li P; Li Q; Chen L; Sun Y; Zhang J
    Pharmazie; 2008 Oct; 63(10):748-50. PubMed ID: 18972838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CD40 and thyroglobulin genes with later-onset Graves' disease in Taiwanese patients.
    Hsiao JY; Hsieh MC; Hsiao CT; Weng HH; Ke DS
    Eur J Endocrinol; 2008 Nov; 159(5):617-21. PubMed ID: 18755875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between thyroglobulin gene polymorphisms and autoimmune thyroid disease.
    Wang LQ; Wang TY; Sun QL; Qie YQ
    Mol Med Rep; 2015 Sep; 12(3):4469-4475. PubMed ID: 26099577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease.
    Eliana F; Suwondo P; Asmarinah A; Harahap A; Djauzi S; Prihartono J; Pemayun TGD
    Acta Med Indones; 2017 Jul; 49(3):195-204. PubMed ID: 29093229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
    El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
    J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves' disease relapse after antithyroid drug withdrawal: a follow-up study.
    Wang PW; Chen IY; Liu RT; Hsieh CJ; Hsi E; Juo SH
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2513-8. PubMed ID: 17426089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the thyroglobulin gene polymorphism with autoimmune thyroid disease in Chinese population.
    Maierhaba M; Zhang JA; Yu ZY; Wang Y; Xiao WX; Quan Y; Dong BN
    Endocrine; 2008 Jun; 33(3):294-9. PubMed ID: 19034705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the medical treatment of Graves' disease (GD)].
    Peixoto MC; Coeli CM; Vaisman M
    Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valuable predictive features of relapse of Graves' disease after antithyroid drug treatment.
    Liu X; Shi B; Li H
    Ann Endocrinol (Paris); 2015 Dec; 76(6):679-83. PubMed ID: 26514949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent remission of Graves` disease or evolution from Graves' disease to Hashimoto's thyroiditis in childhood - a report of 6 cases and clinical implications.
    Smyczńyska J; Cyniak-Magierska A; Stasiak M; Karbownik-Lewińska M; Lewiński A
    Neuro Endocrinol Lett; 2014; 35(5):335-41. PubMed ID: 25275265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.